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Aims Pulmonary arterial hypertension (PAH) occurs more frequently in women than men. Oestrogen and the oestrogen-
metabolising enzyme cytochrome P450 1B1 (CYP1B1) play a role in the development of PAH. Anorectic drugs such
as dexfenfluramine (Dfen) have been associated with the development of PAH. Dfen mediates PAH via a serotoner-
gic mechanism and we have shown serotonin to up-regulate expression of CYP1B1 in human pulmonary artery
smooth muscle cells (PASMCs). Thus here we assess the role of CYP1B1 in the development of Dfen-induced PAH.
Methods
and results
Dfen (5 mg kg21 day21 PO for 28 days) increased right ventricular pressure and pulmonary vascular remodelling in
female mice only. Mice dosed with Dfen showed increased whole lung expression of CYP1B1 and Dfen-induced PAH
was ablated in CYP1B12/2 mice. In line with this, Dfen up-regulated expression of CYP1B1 in PASMCs from PAH
patients (PAH-PASMCs) and Dfen-mediated proliferation of PAH-PASMCs was ablated by pharmacological inhibition
of CYP1B1. Dfen increased expression of tryptophan hydroxylase 1 (Tph1; the rate-limiting enzyme in the synthesis
of serotonin) in PAH-PASMCs and both Dfen-induced proliferation and Dfen-induced up-regulation of CYP1B1 were
ablated by inhibition of Tph1. 17b-Oestradiol increased expression of both Tph1 and CYP1B1 in PAH-PASMCs, and
Dfen and 17b-oestradiol had synergistic effects on proliferation of PAH-PASMCs. Finally, ovariectomy protected
against Dfen-induced PAH in female mice.
Conclusion CYP1B1 is critical in the development of Dfen-induced PAH in mice in vivo and proliferation of PAH-PASMCs in vitro.
CYP1B1 may provide a novel therapeutic target for PAH.
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1. Introduction
Pulmonary arterial hypertension (PAH) is a progressive disease of the
pulmonary vasculature resulting in right heart failure and death. In its
idiopathic and familial forms, PAH occurs more frequently in females
than in males.1–3 Recent evidence suggests a role for oestrogen and
the oestrogen-metabolising enzyme cytochrome P450 1B1 (CYP1B1)
in the development of PAH. 17b-Oestradiol (the predominant circulat-
ing oestrogen) up-regulates components of the serotonin signalling
system and mediates proliferation of human pulmonary artery
smooth muscle cells (hPASMCs).4,5 In line with this, female gender is
permissive in the development of PAH in mice which over-express
the serotonin transporter (SERT+ mice) or S100A4/Mts1 (which func-
tions downstream of serotonin).4,5 The PAH phenotype in female
SERT+ mice is reversed by ovariectomy but restored following
17b-oestradiol replacement.5
CYP1B1 is a P450 enzyme expressed in the lung catalysing the con-
version of oestrogens predominantly to 4-hydroxyoestrogens, but
also to 2-hydroxy and 16-hydroxyoestrogens.6,7 CYP1B1 gene poly-
morphisms and dysregulated CYP1B1 expression have been asso-
ciated with the risk of developing lung and other cancers,8,9 primary
congenital glaucoma,10 and systemic hypertension.11 Multiple lines
of evidence from both human and mouse show a role for CYP1B1
in the development of PAH. CYP1B1 gene expression is dysregulated
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in B-lymphocytes cultured from female PAH patients harbouring a
bone morphogenetic protein receptor type II (BMPRII) mutation.12
Interestingly, cytoskeletal defects are observed in pulmonary artery
endothelial cells (PAECs) derived from BMPR2 mutated, pulmonary
hypertensive mice.13 We have recently shown that CYP1B1 expres-
sion is increased in the pulmonary vasculature from patients with
PAH. In mice, genetic or pharmacological inhibition of CYP1B1 can
protect against experimental PAH.14 Interestingly, serotonin can in-
crease expression of CYP1B1 in hPASMCs.15
The anorectic agents aminorex and dexfenfluramine have been
associated with the development of PAH since the 1960s and
1980s, respectively.16,17 Both aminorex and fenfluramine are sero-
tonin transporter (SERT) substrates and increase extracellular con-
centrations of serotonin,18 leading to the hypothesis that these
drugs mediate PAH via a serotonergic mechanism. In support of
this hypothesis, we have shown that female mice deficient in Tph1
are protected against Dfen-induced PAH.19 Identification of the
precise mechanism by which Dfen mediates PAH is essential to iden-
tify (i) other drugs which may be risk factors for development of the
disease and (ii) cohorts of patients who have an increased risk of
developing PAH in response to these drugs. Recently increased inci-
dence of PAH has been noted in patients taking the drugs metamphe-
tamine20 and benfluorex,21 both of which are structurally similar to
and share pharmacological properties with Dfen. In the current
study, we assess the role of CYP1B1 in the development of
Dfen-induced PAH both in vivo and in vitro.
2. Methods
2.1 Ethical information
The investigation conforms with the UK Animal procedures act, 1986,
with the Guide for the Care and Use of Laboratory Animals published
by the US National Institutes of Health (NIH publication, 8th Edition,
2011). Experimental procedures using hPASMCs conform to the princi-
ples outlined in the Declaration of Helsinki. Ethical approval was also
granted by the University Ethics Committee.
2.2 CYP1B12/2 mice
CYP1B12/2 mice were generously provided to us by the National Cancer
Institute, Bethesda, MD, USA. The mice were generated on a C57BL/6
background as previously described.22 Age-matched C57BL/6 mice were
studied as controls.
2.3 Dfen administration
C57BL/6 mice and CYP1B12/2 mice (10–12 weeks old) were adminis-
tered Dfen (Sigma, Poole, UK) at a dose of 5 mg kg21 day21 by oral
gavage, for 28 days. The vehicle was distilled H2O.
2.4 Bilateral ovariectomy
Female C57BL/6 mice were bilaterally ovariectomized at 8–10 weeks of
age. The 28-day Dfen dosing regime commenced 2 weeks post-surgery.
To determine the success of the ovariectomy procedure, the uterus
was removed and weighed at necroscopy. Inhalation anaesthesia was
used throughout the procedure (1–3% isofluorane supplemented with
oxygen). Depth of anaesthesia was assessed by loss of pain and corneal
reflexes.
2.5 Assessment of PAH
2.5.1 In vivo haemodynamic measurements
Mice were anaesthetised as described above. Pressure measurements
were conducted and analysed as described previously.23 Briefly, right ven-
tricular pressure was measured via a 25-gauge needle advanced into the
right ventricle using a transdiaphragmatic approach. Systemic arterial pres-
sure was obtained via a microcannula inserted into the carotid artery.
Mice were euthanized by cervical dislocation and heart and lungs
removed for subsequent analysis as described below. Ten to 12 mice
per group were studied.
2.5.2 Lung histology
Sagittal lung sections were stained with Elastica-Van Gieson and micro-
scopically assessed for muscularization of small pulmonary arteries
(,80 mm external diameter) in a blinded fashion, as described previous-
ly.19 Remodelled arteries were confirmed by the presence of a double
elastic laminae. Lung sections from four to six mice from each group
were studied.
2.5.3 Measurement of right ventricular hypertrophy
Right ventricular hypertrophy (RVH) was assessed by measuring the
weight of the RV free wall and expressing this as a ratio of the weight
of the left ventricle together with the septum (LV + S).
2.6 Cells
Three distal PASMC lines (each from an individual PAH patient) were
used in this study. Cells were explanted immediately following pneumon-
ectomy, and were provided to us by Prof NW Morrell, University of Cam-
bridge, UK. Clinical data from the three PAH patients are shown in
Table 1. PAECs were obtained from Promocell (Germany).
2.7 Proliferation assays
PAH-PASMCs (passages 3–6) were grown to 40% confluency prior to
24 h growth arrest in phenol-red free 0.2% foetal bovine serum (FBS)
DMEM. PAH-PASMCs were then exposed to Dfen, norfenfluramine, or
17b-oestradiol for 72 h. For antagonist studies, the Tph inhibitor para-
chlorophenylalanine (PCPA; 10 mmol/L) or the CYP1B1 inhibitor
2,3′,4,5′-tetramethoxystilbene (TMS; 1 mmol/L) was added 30 min prior
to the addition of Dfen. As quiescent PASMCs do not readily proliferate,
all experiments were performed in the presence of either 2.5% FBS or
10 ng/mL platelet-derived growth factor (PDGF). DMEM and agonists/
antagonists were replaced every 48 h. For the final 24 h, 0.2 mCi [3H]
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1. Clinical details and classification of the PAH patients from whom the three PAH-PASMC lines were derived
Patient Age Gender Classification Pulmonary artery pressure (mmHg)
(systolic/mean/diastolic)
1 41 F IPAH 90/58/40
2 34 M FPAH 74/38/24
3 24 F IPAH 83/60/30
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thymidine was added to each well. Cells were then lysed as described pre-
viously19 and [3H] thymidine incorporation measured. Data are expressed
as fold change compared with control. All experiments were conducted at
least in triplicate from a minimum of two PAH-PASMC lines. Thymidine is
incorporated into replicating chromosomal DNA during mitosis and
measurement of [3H] thymidine incorporation is an extremely accurate
method of measuring human PASMC proliferation. Indeed, we have pre-
viously reported high correlation with alternative proliferation assays in
this cell type.5
2.8 RNA preparation and qRT-PCR
PAH-PASMCs were grown to 80% confluency in 12-well plates and
quiesced in phenol-red free DMEM for 24 h before treatment with
Dfen (0.3–3 mmol/L) or 17b-oestradiol (0.1–1 nmol/L) for 4 h. All
experiments were conducted at least in triplicate from a minimum of
two PAH-PASMC lines. Total RNA was isolated using miRNeasy Mini
Kit (Qiagen) and reverse-transcribed using Taqman reverse transcription
kit (Applied Biosystems) according to the instructions of the manufactur-
er. Quantitative real-time PCR was performed using Universal master mix
II with Assays on Demand gene expression probes (system and probes
from Applied Biosystems) for Tph1 (assay ID: Hs00188220_m1) and
CYP1B1 (assay ID: Hs02382916_s1) using the comparative delta-CT
method with b2-microglobulin as the endogenous control. qRT-PCR for
CYP1B1 was also performed on whole lung isolated from Dfen-dosed
mice (n ¼ 6 per group) using the gene expression probe
Mm00487229_m1.
2.9 Western blot analysis
Cells were grown to 80% confluency in six-well plates and quiesced in
phenol-red free DMEM for 24 h before treatment with Dfen (0.3–
3 mmol/L) or 17b-oestradiol (0.1–1 nmol/L) for 4 h. Cell lysates were
then prepared for immunoblots as described previously.19 Primary anti-
bodies used were rabbit anti-Tph1 (1:500, Abcam, UK), rabbit
anti-CYP1B1 (1:1000, Abcam, UK), and mouse anti-alpha tubulin
(1:5000; Abcam UK). Densitometrical analysis was performed using the
TotalLab TL100 software. PAH-PASMC experiments were performed in
triplicate from a minimum of two PAH-PASMC lines. PAEC experiments
were performed in triplicate.
2.10 Serotonin ELISA assay
Serotonin concentration in conditioned media derived from PASMCs
exposed to Dfen for 24 h was quantified by ELISA analysis (Genway
Biotech, USA). Experiments were carried out in duplicate from each of
the three PAH-PASMC lines.
2.11 Statistical analysis
Statistical comparisons were made by one-way analysis of variance with
Dunnett’s post-test, two-way analysis of variance followed by Bonferroni’s
post-test, or Student’s t-test as appropriate. Data are expressed as
mean+ SEM.
3. Results
3.1 Dfen-induced PAH is observed only
in female mice
We have previously shown female gender bias in mouse models of
disease where the serotonin signalling system is enhanced.4,5 Hence,
we examined the development of Dfen-induced PAH in both male
and female mice and observed that Dfen-induced PAH only occurred
in female mice. In female mice, there was an increase in systolic RVP
(sRVP; n ¼ 6–10) and pulmonary vascular remodelling (n ¼ 4) follow-
ing Dfen administration (Figure 1A–C). RVH was significantly higher in
vehicle-dosed male mice than in vehicle-dosed female mice; however,
Dfen ingestion had no further effects on RVH (Figure 1D, n ¼ 8–10).
Mean systemic arterial pressure (mSAP, n ¼ 7–10) and heart rate
(n ¼ 10–12) were unaffected by gender or Dfen administration
(Figure 1E and F ).
3.2 CYP1B1 influences the development
of Dfen-induced PAH in vivo
Serotonin and 17b-oestradiol can up-regulate the oestrogen-
metabolizing enzyme CYP1B115 which has been shown to play a
role in the development of PAH.14 Therefore, we assessed the role
of CYP1B1 on development of Dfen-induced PAH in female mice.
We observed increased expression of CYP1B1 in the lungs of
female Dfen-dosed mice by qRT-PCR (Figure 2A, n ¼ 6). Moreover,
female CYP1B12/2 mice were protected against Dfen-induced
increases in sRVP (Figure 2B, n ¼ 9–12) and pulmonary vascular re-
modelling (Figure 2C and D, n ¼ 4–5). RVH (Figure 2E, n ¼ 8–12),
mSAP (Figure 2F, n ¼ 7–11), and heart rate (Figure 2G, n ¼ 8–12)
were unaffected by Dfen administration or genetic ablation of
CYP1B1.
3.3 CYP1B1 is critical for Dfen-induced
proliferation of PAH-PASMCs in vitro
Having shown a critical role for CYP1B1 in the development of
Dfen-induced PAH in vivo, we assessed the direct effects of Dfen on
proliferation of PAH-PASMCs in vitro and the role of CYP1B1 in
these effects. Dfen stimulated proliferation of PAH-PASMCs in the
presence of 2.5% serum (Figure 3A, n ¼ 3) or 10 ng/mL PDGF
(Figure 3B, n ¼ 3). All subsequent proliferation experiments were
carried out in the presence of 2.5% serum. Dfen-induced proliferation
was associated with an increase in protein expression of CYP1B1
(Figure 3C, n ¼ 3) and was inhibited by the selective CYP1B1 inhibitor
TMS (Figure 3D, n ¼ 3). As the active Dfen metabolite norfenflura-
mine has also been implicated in the development of PAH,24 we
assessed the effects of norfenfluramine on proliferation of PAH-
PASMCs. Norfenfluramine did not mediate proliferation of PAH-
PASMCs (Figure 3E, n ¼ 3).
3.4 CYP1B1 functions downstream
of serotonin in Dfen-induced proliferation
of PAH-PASMCs
As we have previously shown that Dfen-induced PAH is dependent
on peripheral serotonin in vivo,19 we investigated the role of serotonin
in the effects of Dfen on PAH-PASMCs in vitro. First, we show that
Dfen can up-regulate both mRNA (Figure 4A, n ¼ 3) and protein
(Figure 4B, n ¼ 3) expression of Tph1 in PAH-PASMCs. In addition,
serotonin concentration was increased in conditioned media
derived from cells treated with Dfen (Figure 4C, n ¼ 3). The Tph1 in-
hibitor PCPA inhibited both Dfen-induced up-regulation of CYP1B1
(Figure 4D, n ¼ 3) and Dfen-induced proliferation of PAH-PASMCs
(Figure 4E, n ¼ 4). As endothelial cells play an important role in the
development of PAH, we also assessed whether Dfen could
up-regulate CYP1B1 or Tph1 in endothelial cells. Dfen had no
effects on CYP1B1 expression in PAECs (Supplementary material
online, Figure S1A). Dfen mediated a trend (although not statistically
significant) towards increased Tph1 expression in endothelial cells
(Supplementary material online, Figure S1B).
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3.5 17b-Oestradiol plays a role in the
development of Dfen-induced PAH
Finally, we wished to investigate the role of female sex hormones on
the development of Dfen-induced PAH. We have previously shown
that 17b-oestradiol can up-regulate expression of both CYP1B1 and
Tph1 in human PASMCs from non-diseased controls.5,15 Now we
confirm that CYP1B1 (Figure 5A, n ¼ 3) and Tph1 (Figure 5B, n ¼ 3)
are up-regulated by 17b-oestradiol in PAH-PASMCs. In line with
this, Dfen and 17b-oestradiol have synergistic effects on the prolifer-
ation of PAH-PASMCs (Figure 5C, n ¼ 3). 17b-Oestradiol had no
effects on CYP1B1 or Tph1 expression in PAECs (Supplementary
material online, Figure S2). To confirm these findings in vivo, we
assessed whether Dfen-induced PAH was ablated in ovariectomized
mice. Success of the ovariectomy procedure was confirmed by a
marked reduction of uterus weight (sham-operated mice 64.1+
4.3 mg cf ovariectomized mice 7.4+0.4 mg, n ¼ 24 per group, P,
0.001). Indeed, we show that Dfen-induced increases in sRVP
(Figure 6A, n ¼ 9–11) and pulmonary vascular remodelling
(Figure 6B and C, n ¼ 4) are reduced in ovariectomized mice. As
described previously,5 ovariectomy increased sRVP and pulmonary
vascular remodelling in vehicle-dosed mice (Figure 6A and B). There
were no changes in RVH (n ¼ 12), mSAP (n ¼ 7–10), or heart rate
(n ¼ 9–12) in any of the groups studied (Figure 6D–F ).
Figure 1. The effects of Dfen on mediation of PAH are specific to female mice. Dfen-induced increases in (A) sRVP (n ¼ 6, 6, 10, 6, respectively)
and (B) pulmonary vascular remodelling (n ¼ 4) were specific to female mice. (C) Representative images of resistance pulmonary arteries (stained with
Elastica-Van Gieson) showing increased remodelling in female Dfen-dosed mice only. Male mice show a modest increase in (A) sRVP and (D) RVH
(n ¼ 10, 9, 8, 8, respectively) compared with female mice. Dfen administration has no further effects on RVH. (E) mSAP (n ¼ 7, 8, 7, 10, respectively)
and (F) heart rate (n ¼ 10, 10, 12, 10, respectively) are unchanged between any of the groups studied. Data are expressed as mean+ SEM. Data were
analysed by two-way ANOVA followed by Bonferroni’s post-test. *P, 0.05, ***P, 0.001 vs. female vehicle-dosed mice †††P, 0.001 vs. female Dfen
dosed mice. Scale bars represent 20 mm.
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Figure 2. CYP1B1 is critical for Dfen-induced PAH. (A) CYP1B1 expression was increased in Dfen-dosed mice as assessed by qRT-PCR (n ¼ 6). (B)
Dfen induced increases in sRVP (n ¼ 9, 9, 9, 12, respectively) and (C) pulmonary vascular remodelling (n ¼ 4, 4, 4, 5, respectively) were ablated in
female CYP1B12/2 mice. (D) Representative images of resistance pulmonary arteries (stained with Elastica-Van Gieson) showing Dfen-induced re-
modelling is ablated in female CYP1B12/2 mice. (E) RVH (n ¼ 8, 10, 9, 12, respectively), (F ) mSAP (n ¼ 7, 11, 8, 11), and (G) heart rate (n ¼ 8,
11, 8, 12, respectively) were unchanged by Dfen administration or genetic ablation of CYP1B1. Data are expressed as mean+ SEM. Data were ana-
lysed by two-way ANOVA followed by Bonferroni’s post-test. f fP, 0.01 vs. vehicle, **P, 0.01, ***P, 0.001 vs. female wild-type vehicle-dosed
mice, ††P, 0.01, †††P, 0.001 vs. female wild-type Dfen-dosed mice. Scale bars represent 20 mm.
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4. Discussion
Here, we show a critical role for female sex hormones and the
oestrogen-metabolizing enzyme CYP1B1 in the development of
Dfen-induced PAH in mice. In order to translate our findings to
human disease, we assessed the effects of Dfen in PASMCs derived
from PAH patients. In these cells, we show that Dfen can increase
CYP1B1 expression and Dfen-induced proliferation is dependent on
CYP1B1 activity. We verify the role of serotonin in Dfen-mediated
PAH by showing that Dfen can act directly on PAH-PASMCs to in-
crease expression of Tph1, and pharmacological inhibition of Tph1
can inhibit both Dfen-induced proliferation and Dfen-induced
up-regulation of CYP1B1. Further, we show that 17b-oestradiol can
increase Tph1 and CYP1B1 expression in PAH-PASMCs and in line
with this, Dfen and 17b-oestradiol have synergistic effects on prolifer-
ation of PAH-PASMCs.
We have recently described a pivotal role for CYP1B1 in the devel-
opment of experimental PAH and in human PAH14 and the data
shown here provide the first evidence in support of a role for
CYP1B1 in a model of anorexigen-induced PAH. CYP1B1 catalyses
the formation of metabolites including 2,4 and 16a-hydroxyoestro-
gens from 17b-estradiol.6,7 16a-Hydroxyoestrone (but not two or
four hydroxyoestrogen) mediates proliferation of hPASMCs, an
effect which is exaggerated in cells from PAH patients. In line with
Figure 3. CYP1B1 is critical for Dfen-induced proliferation of PAH-PASMCs. (A and B) Dfen-mediated proliferation of PAH-PASMCs in the pres-
ence of both FBS (n ¼ 3) or PDGF (n ¼ 3). (C) Dfen up-regulates expression of CYP1B1 in PAH-PASMCs as assessed by western blot (n ¼ 3). (D)
Dfen-mediated proliferation is inhibited in the presence of the selective CYP1B1 inhibitor TMS (1 mM) (n ¼ 3). (E) Norfenfluramine had no effect on
proliferation of PAH-PASMCs (n ¼ 3). Data are expressed as mean+ SEM. Data were analysed by one-way ANOVA followed by Dunnett’s post-test.
*P, 0.05, **P, 0.01 vs. 2.5% serum or 10 ng/mL PDGF, fP, 0.05, f fP, 0.01 vs. control †P, 0.05 vs. Dfen.
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this, administration of 16a-hydroxyoestrone leads to the develop-
ment of PAH in mice.14 Although CYP1B1 can mediate formation
of 2-hydroxyoestrogens, these are predominantly formed by the
CYP1A1/2 enzymes.6,7,14 2-Hydroxyestradiol is further converted to
2-methoxyestradiol via catechol O-methyltransferase. 2-Methoxyes-
tradiol has been shown to be protective in the development of
PAH in rodent models and also to have anti-proliferative effects on
cells.25 Thus, the effects of CYP1B1 on the development of PAH
may be due to a shift in the balance of oestrogen conversion to
favour the pro-proliferative metabolites. In line with this, a decreased
2 hydroxyoestrogen:16a-hydroxyoestrogen ratio has been associated
with PAH penetrance in female BMPRII mutation carriers.26
We have previously shown that Dfen-induced PAH in vivo is de-
pendent on the activity of Tph1 (the Tph isoform responsible for syn-
thesis of serotonin in the periphery).19 However, the serotonin
hypothesis of PAH is still debated,27 firstly because fenfluramine-
induced elevations in whole blood serotonin levels are below those
necessary to induce cardiovascular side effects and secondly
because compensatory genetic changes in Tph12/2 mice may be
involved in the protection of these mice from Dfen-induced PAH.
We have hypothesized that Dfen mediates its effects directly on the
cells of the pulmonary vasculature,28,29 which would explain why
Dfen can mediate PAH via a serotonergic mechanism without
raising whole blood serotonin to toxic levels. In the current study,
Figure 4. CYP1B1 functions downstream of Tph1 in Dfen-induced proliferation of PAH-PASMCs. Dfen up-regulates (A) mRNA (n ¼ 3) and (B)
protein (n ¼ 3) expression of Tph1. (C) There is an increased concentration of serotonin in conditioned media derived from cells treated with
Dfen (n ¼ 3). (D) Dfen-induced up-regulation of CYP1B1 (n ¼ 3) and (E) Dfen-induced proliferation (n ¼ 4) are inhibited in the presence of the
Tph1 inhibitor PCPA (10 mM). Data are expressed as mean+ SEM. Data were analysed by one-way ANOVA followed by Dunnett’s post-test.
*P, 0.05, **P, 0.01 vs. control, §§P, 0.01 vs. 2.5% serum, †P, 0.05, ††P, 0.01 vs. Dfen.
Dexfenfluramine and CYP1B1 in PAH Page 7 of 11
 at Periodicals D
ept on M
ay 17, 2013
http://cardiovascres.oxfordjournals.org/
D
ow
nloaded from
 
we clarify this hypothesis. First, we detected Tph1 protein in PAH-
PASMCs and have shown that Dfen increases expression of Tph1
protein in these cells. Further, Dfen-induced activation of CYP1B1
and Dfen-induced proliferation of PAH-PASMCs are abolished with
the Tph inhibitor PCPA, confirming the importance of de novo pul-
monary arterial serotonin synthesis in response to Dfen. Dfen has
previously been reported to have direct effects on pulmonary arter-
ies, including inhibition of potassium channels,30 increased intracellular
calcium,31 vasoconstriction,32 and mitogenic effects.33 However, the
role of Tph1 in mediation of these effects remains to be assessed.
The major metabolite of Dfen, norfenfluramine, is an agonist at the
5-HT2A and 5-HT2B receptors,
34 both of which have been implicated
in experimental PAH.35,36 In addition, norfenfluramine has been
shown to cause more severe pulmonary vasoconstriction than Dfen
in rat pulmonary arteries.24 We did not observe any effects of norfen-
fluramine on PAH-PASMC proliferation. Thus, while it is likely that
norfenfluramine contributes to Dfen-induced PAH by mediating vaso-
constriction, our results do not support a role for norfenfluramine in
proliferation of PAH-PASMCs. Our results suggest that Dfen, which is
a SERT substrate,34 enters the cell via SERT and increases de novo syn-
thesis of serotonin via induction of Tph1. Serotonin can then
up-regulate expression of CYP1B1.
17b-Oestradiol circulates at concentrations of 0.1–1 nmol/L.37
Here, we show that physiological concentrations of 17b-oestradiol
stimulated both Tph1 and CYP1B1 expression in PAH-PASMCs.
Both Dfen and 17b-oestradiol mediate proliferation of hPASMCs
and these effects are synergistic at 0.3 mmol/L and 0.1 nmol/L, re-
spectively, which are within therapeutic (Dfen) and physiological
(17b-oestradiol) concentration ranges. This may indeed explain why
Dfen-induced PAH was not observed in the male mice where circu-
lating 17b-oestradiol is very low. Consistent with the data we
present here, clinical studies have demonstrated a female gender
bias towards Dfen-induced PAH in humans. In one study, a much
larger proportion (40.9%) of female primary pulmonary hypertensive
patients had used anorexigenic drugs than male primary pulmonary
hypertensive patients (10.3%).16 In addition, in different patient popu-
lations, the ratio of women to men with anorexigenic-induced PAH
has been reported to be 8:1, 30:1, and 34:1.38–40 It has always been
assumed that the gender imbalance in the development of
Dfen-induced PAH was due to a higher proportion of females using
appetite suppressant drugs. However, the current study suggests a
female pre-disposition to PAH in response to Dfen exposure. One
limitation of our model, however, is that in the human condition,
males develop Dfen-induced PAH whereas male mice do not. In
Figure 5. 17b-Oestradiol and Dfen have synergistic effects on PAH-PASMC proliferation. 17b-Oestradiol mediates an increase in (A) CYP1B1
(n ¼ 3) and (B) Tph1 (n ¼ 3) expression in PAH-PASMCs. (C) Dfen and 17b-oestradiol have synergistic effects on proliferation of PAH-PASMCs
(n ¼ 3). Data are expressed as mean+ SEM. Data were analysed by one-way ANOVA followed by Dunnett’s post-test. *P, 0.05 vs. 0.3 mM
Dfen P, 0.01 vs. 0.1 nM 17b-estradiol, **P, 0.01 vs. control.
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addition, not all women who took Dfen developed the disease. It is of
interest that BMPRII mutations have been associated with the devel-
opment of fenfluramine-induced PAH,39 and polymorphisms in the
gene encoding CYP1B1 increase disease penetrance in BMPRII muta-
tion carriers by four-fold.26 Thus, assessment of CYP1B1 polymorph-
isms in patients with Dfen-induced PAH would be informative.
Interestingly, male C57BL/6 mice showed slightly higher sRVP and
RVH than female mice and ovariectomy increased sRVP and pulmon-
ary vascular remodelling in vehicle-dosed wild-type mice. This sug-
gests that in the absence of activation of the serotonin system,
female sex hormones may actually be protective. Indeed, oestrogen
has recently been shown to be protective against hypoxic-induced
PAH in male rats,41 and progesterone can protect against
monocrotaline-induced PAH.42 As discussed above, as well as the
formation of pro-proliferative metabolites, oestrogen metabolism
can also lead to the formation of anti-proliferative metabolites. Inter-
estingly, serotonin has been shown to up-regulate CYP1B1 in
hPASMCs and in the current study we have shown Dfen to activate
CYP1B1 via a serotonergic mechanism. In line with this, CYP1B1 ex-
pression is enhanced in female Dfen-dosed mice and in female mice
over-expressing the serotonin transporter.15 Thus, our results
suggest that enhanced serotonin signalling may lead to activation of
CYP1B1, which can disrupt the balance of oestrogen metabolites to
favour pro-proliferative forms.
In the present study, female mice developed increased RVP follow-
ing Dfen-administration; however, RVH remained unaffected. We
have previously shown a dissociation between RVP and RVH in the
SERT+ mouse, mice over-expressing S100A4/Mts1, and mice dosed
Figure 6. Female sex hormones are critical for Dfen-induced PAH. Dfen-induced increases in (A) sRVP (n ¼ 11, 11, 9, 9, respectively) and (B) pul-
monary vascular remodelling (n ¼ 4) were inhibited in ovariectomized mice. Ovariectomized mice show a modest increase in sRVP (A) and pulmonary
vascular remodelling (B) compared with sham-operated controls. (C) Representative images of resistance pulmonary arteries stained with Elastica-Van
Gieson. Dfen administration or ovariectomy had no effects on (D) RVH (n ¼ 12), (E) mSAP (n ¼ 10, 7, 9, 9, respectively), and (F ) heart rate (n ¼ 11,
12, 9, 10, respectively). Data are expressed as mean+ SEM. Data were analysed by two-way ANOVA followed by Bonferroni’s post-test. **P, 0.001,
***P, 0.001 vs. female vehicle-dosed mice ††P, 0.01, †††P, 0.001 vs. female Dfen-dosed mice. Scale bars represent 20 mm.
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with Dfen.4,19,43 We are not alone in observing this phenomenon as
other studies have also demonstrated elevated RVP in the absence
of RVH in mice.44,45 For example, mice that express BMPR2R899X in
smooth muscle or molecular loss of BMPR2 signalling in smooth
muscle demonstrate elevated RVP with no RVH.44 Interestingly, it
has recently been shown that in mice, testosterone may mediate
RVH in response to load stress, while having no significant effects
on pulmonary haemodynamics.46 Thus it is possible that sex hor-
mones may influence RVH independently of pulmonary haemodynam-
ics. In line with this, we show in the current study that male mice at
baseline have increased RVH compared with female mice.
In conclusion, we have shown that Dfen up-regulates CYP1B1 via a
serotonergic mechanism in PAH-PASMCs and CYP1B1 is critical for
the development of Dfen-induced PAH in mice, and Dfen-induced
proliferation of PAH-PASMCs. Our results suggest that females may
have increased pre-disposition to anorexigen-induced PAH, and
that further investigation of CYP1B1 as a therapeutic target for
anorexigen-induced PAH may be warranted.
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